地塞米松植入剂治疗糖尿病黄斑水肿:初治与难治眼的24个月多中心真实世界研究
这项国际多中心回顾性研究评估了地塞米松植入剂在24个月内对初治与抗VEGF难治性糖尿病黄斑水肿眼的疗效与安全性。共纳入130眼(初治71眼,难治59眼),两组视力均显著改善,但初治眼视力增益显著更大(+11.3±10.0 vs 7.3±2.7 letters,P=0.01),且更可能获得≥10字母增益(OR 3.31,95%CI 1.19-9.24,P=0.02)。
要点
- 初治眼较难治眼视力增益更大(+11.3±10.0 vs 7.3±2.7 letters,P=0.01)。
- 初治眼更可能获得≥10字母增益(OR 3.31,95%CI 1.19-9.24,P=0.02)。
- 两组黄斑中心凹厚度较基线显著下降,但难治眼CST高于初治眼(279±61 vs 313±125 μm,P=0.10)。
核心结论
- 在24个月随访中,地塞米松植入剂治疗使初治和抗VEGF难治性糖尿病黄斑水肿眼视力均改善,但初治眼改善更大。
研究设计与样本
- 国际多中心回顾性研究,纳入130眼来自125例患者,初治组71眼,难治组59眼,评估地塞米松植入剂重复治疗24个月的疗效与安全性。
主要发现
- 初治组与难治组基线最佳矫正视力和黄斑中心凹厚度相似。
- 两组24个月视力均较基线显著改善(P<0.001)。
- 初治组视力增益显著大于难治组(+11.3±10.0 vs 7.3±2.7 letters,P=0.01)。
- 初治组获得≥10字母增益的可能性更高(OR 3.31,95%CI 1.19-9.24,P=0.02)。
- 第6、12、24个月两组黄斑中心凹厚度均较基线显著下降,但难治组CST高于初治组(279±61 vs 313±125 μm,P=0.10)。
关键数值与推荐
- 初治组视力增益+11.3±10.0 letters,难治组+7.3±2.7 letters,P=0.01。
- 获得≥10字母增益的OR为3.31(95%CI 1.19-9.24,P=0.02),初治组更可能。
- 第24个月CST初治组279±61 μm,难治组313±125 μm,P=0.10。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate efficacy and safety of repeated dexamethasone (DEX) implants over 24 months, in diabetic macular edema (DME) eyes that were treatment naive compared with eyes refractory to anti-vascular endothelial growth factor treatment, in a real-life environment. METHODS: This multicenter international retrospective study assessed best-corrected visual acuity and central subfield thickness (CST) of naive and refractory eyes to anti-vascular endothelial growth factor injections treated with dexamethasone implants. Safety data (intraocular pressure rise and cataract surgery) were recorded. RESULTS: A total of 130 eyes from 125 patients were included. Baseline best-corrected visual acuity and CST were similar for naive (n = 71) and refractory eyes (n = 59). Both groups improved significantly in vision after 24 months (P < 0.001). However, naive eyes gained statistically significantly more vision than refractory eyes (+11.3 ± 10.0 vs. 7.3 ± 2.7 letters, P = 0.01) and were more likely to gain ≥10 letters (OR 3.31, 95% CI 1.19-9.24, P = 0.02). At 6, 12, and 24 months, CST was significantly decreased compared with baseline in both naive and refractory eyes; however, CST was higher in refractory eyes than in naive eyes (CST 279 ± 61 vs. 313 ± 125 μm, P = 0.10). CONCLUSION: Over a follow-up of 24 months, vision improved in diabetic macular edema eyes after treatment with dexamethasone implants, both in eyes that were treatment naive and eyes refractory to anti-vascular endothelial growth factor treatment; however, improvement was greater in naive eyes.
引用
- Iglicki M, Busch C, Zur D, et al. DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina. 2019. PMID: 29697589. doi:10.1097/IAE.0000000000002196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。